Skip to main content
Fig. 2 | Trials

Fig. 2

From: Testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1–11-month-old infants in Mali (LAKANA): study protocol for a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial

Fig. 2

Schedule of enrolment, intervention, and follow-up assessments for the LAKANA trial. aNo upper or lower limit in the number of participants per study village, i.e., all households and infants who can be enrolled or treated with study drugs during any MDA visit will be included in the study. bMaximum number of treatments given to any single individual 1–11-month-old infant is four. cData collection on secondary outcomes only in the subset of villages selected for the AMR monitoring. AMR, antimicrobial resistance; AZI, azithromycin; LAKANA, Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regimens with Azithromycin; MDA, mass drug administration; SMC, seasonal malaria chemoprevention

Back to article page

Trials

ISSN: 1745-6215